Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | ||
Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Esophageal carcinoma, gastroesophageal junction adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Dojolvi | triheptanoin | Long-chain fatty acid oxidation disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | nivolumab | Esophageal or gastroesophageal junction cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Onureg | azacitidine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete |